HER2 therapy--an abundance of riches.

  title={HER2 therapy--an abundance of riches.},
  author={William John Gradishar},
  journal={The New England journal of medicine},
  volume={366 2},
Human epidermal growth factor receptor 2 (HER2)positive breast cancer is a distinct subset of breast cancer characterized by overexpression of the HER2 protein. Clinically, HER2-positive tumors are associated with a more aggressive phenotype and poor outcomes. With the introduction of trastuzumab, a humanized monoclonal antibody targeting HER2, significant improvements in survival were observed in patients with HER2-positive metastatic breast cancer and in patients with early-stage disease.1,2… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS
15 Citations
12 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 15 extracted citations


Publications referenced by this paper.
Showing 1-10 of 12 references

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

  • HA IIIBurris, HS Rugo, SJ Vukelja
  • J Clin Oncol 2011;29:398-405
  • 2011

Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (‘NeoSphere’)

  • L Gianni, T Pienkowski, YH Im
  • Presented at the 33rd Annual San Antonio Breast…
  • 2010

Similar Papers

Loading similar papers…